Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Genetic Technologies

DB:DU8
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DU8
DB
A$20M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women’s health in Australia and the United States. The last earnings update was 31 days ago. More info.


Add to Portfolio Compare Print
  • Genetic Technologies has significant price volatility in the past 3 months.
DU8 Share Price and Events
7 Day Returns
-50%
DB:DU8
6.3%
Europe Life Sciences
7.1%
DE Market
1 Year Returns
-50%
DB:DU8
20.5%
Europe Life Sciences
-17.5%
DE Market
DU8 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Genetic Technologies (DU8) -50% -85.7% -50% -50% -83.3% -96%
Europe Life Sciences 6.3% -5.8% 0.5% 20.5% 71.6% 174.5%
DE Market 7.1% -20% -26.1% -17.5% -25.8% -29.2%
1 Year Return vs Industry and Market
  • DU8 underperformed the Life Sciences industry which returned 20.5% over the past year.
  • DU8 underperformed the Market in Germany which returned -17.5% over the past year.
Price Volatility
DU8
Industry
5yr Volatility vs Market

DU8 Value

 Is Genetic Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Genetic Technologies. This is due to cash flow or dividend data being unavailable. The share price is €0.001.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Genetic Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Genetic Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:DU8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in AUD A$0.00
ASX:GTG Share Price ** ASX (2020-03-27) in AUD A$0.01
Europe Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 47.14x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Genetic Technologies.

DB:DU8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:GTG Share Price ÷ EPS (both in AUD)

= 0.01 ÷ 0.00

-2.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genetic Technologies is loss making, we can't compare its value to the Europe Life Sciences industry average.
  • Genetic Technologies is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Genetic Technologies's expected growth come at a high price?
Raw Data
DB:DU8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 1.85x
Germany Market PEG Ratio Median Figure of 254 Publicly-Listed Companies 1.2x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Genetic Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Genetic Technologies's assets?
Raw Data
DB:DU8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in AUD A$0.00
ASX:GTG Share Price * ASX (2020-03-27) in AUD A$0.01
Europe Life Sciences Industry PB Ratio Median Figure of 41 Publicly-Listed Life Sciences Companies 3.69x
Germany Market PB Ratio Median Figure of 575 Publicly-Listed Companies 1.43x
DB:DU8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:GTG Share Price ÷ Book Value per Share (both in AUD)

= 0.01 ÷ 0.00

7.1x

* Primary Listing of Genetic Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genetic Technologies is overvalued based on assets compared to the Europe Life Sciences industry average.
X
Value checks
We assess Genetic Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Genetic Technologies has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

DU8 Future Performance

 How is Genetic Technologies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genetic Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.5%
Expected Life Sciences industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Genetic Technologies expected to grow at an attractive rate?
  • Unable to compare Genetic Technologies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Genetic Technologies's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Genetic Technologies's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:DU8 Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 18.5%
Europe Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.2%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:DU8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:DU8 Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-12-31 0 -5 -6
2019-09-30 0 -6 -6
2019-06-30 0 -6 -6
2019-03-31 0 -6 -6
2018-12-31 0 -6 -5
2018-09-30 0 -6 -5
2018-06-30 0 -6 -5
2018-03-31 0 -6 -7
2017-12-31 0 -6 -8
2017-09-30 0 -7 -8
2017-06-30 1 -7 -8
2017-03-31 1 -7 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Genetic Technologies is high growth as no earnings estimate data is available.
  • Unable to determine if Genetic Technologies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:DU8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Genetic Technologies Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DU8 Past Financials Data
Date (Data in AUD Millions) EPS *
2019-12-31 0.00
2019-09-30 0.00
2019-06-30 0.00
2019-03-31 0.00
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 0.00
2017-06-30 0.00
2017-03-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Genetic Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Genetic Technologies's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Genetic Technologies's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Genetic Technologies's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Genetic Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Genetic Technologies has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

DU8 Past Performance

  How has Genetic Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Genetic Technologies's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Genetic Technologies does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Genetic Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Genetic Technologies's 1-year growth to the Europe Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Genetic Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Genetic Technologies Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DU8 Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.01 -5.95 4.28 2.09
2019-09-30 0.02 -6.19 4.34 2.22
2019-06-30 0.03 -6.43 4.41 2.36
2019-03-31 0.07 -5.86 4.18 2.46
2018-12-31 0.11 -5.29 3.97 2.56
2018-09-30 0.15 -5.38 4.02 2.38
2018-06-30 0.19 -5.46 4.08 2.21
2018-03-31 0.22 -6.55 4.66 2.25
2017-12-31 0.25 -7.63 4.89 2.29
2017-09-30 0.38 -8.02 5.27 2.33
2017-06-30 0.52 -8.40 5.83 2.37
2017-03-31 0.66 -8.29 5.84 2.51
2016-12-31 0.80 -8.18 6.02 2.66
2016-09-30 0.81 -8.32 6.11 2.67
2016-06-30 0.82 -8.46 6.19 2.69
2016-03-31 0.99 -8.39 6.76 2.49
2015-12-31 1.15 -8.33 7.33 2.29
2015-09-30 1.58 -8.57 8.03 2.57
2015-06-30 2.01 -8.81 8.73 2.85
2015-03-31 2.91 -9.33 9.00 3.16
2014-12-31 3.80 -9.86 9.28 3.47
2014-09-30 4.18 -9.99 9.35 3.38
2014-06-30 4.56 -10.13 9.42 3.30
2014-03-31 4.10 -10.40 9.58 3.21
2013-12-31 3.64 -10.68 9.73 3.13
2013-09-30 3.51 -9.99 9.71 3.30
2013-06-30 3.38 -9.30 9.68 3.46
2013-03-31 3.46 -7.49 10.26 3.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Genetic Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Genetic Technologies has efficiently used its assets last year compared to the Europe Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Genetic Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Genetic Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Genetic Technologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

DU8 Health

 How is Genetic Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Genetic Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Genetic Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Genetic Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Genetic Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -7.1483799416604E+16x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Genetic Technologies Company Filings, last reported 2 months ago.

DB:DU8 Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 2.86 0.00 3.28
2019-09-30 2.86 0.00 3.28
2019-06-30 1.77 0.00 2.19
2019-03-31 1.77 0.00 2.19
2018-12-31 3.02 0.00 3.23
2018-09-30 3.02 0.00 3.23
2018-06-30 4.71 0.00 5.49
2018-03-31 4.71 0.00 5.49
2017-12-31 7.33 0.00 7.59
2017-09-30 7.33 0.00 7.59
2017-06-30 10.58 0.00 10.99
2017-03-31 10.58 0.00 10.99
2016-12-31 14.71 0.00 15.00
2016-09-30 14.71 0.00 15.00
2016-06-30 11.88 0.00 11.18
2016-03-31 11.88 0.00 11.18
2015-12-31 15.98 0.00 14.52
2015-09-30 15.98 0.00 14.52
2015-06-30 18.96 0.03 18.34
2015-03-31 18.96 0.03 18.34
2014-12-31 0.30 1.50 1.28
2014-09-30 0.30 1.50 1.28
2014-06-30 1.83 2.50 2.83
2014-03-31 1.83 2.50 2.83
2013-12-31 7.28 5.35 8.91
2013-09-30 7.28 5.35 8.91
2013-06-30 5.76 0.00 1.93
2013-03-31 5.76 0.00 1.93
  • Genetic Technologies's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (291% vs 0% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Genetic Technologies has less than a year of cash runway based on current free cash flow.
  • Genetic Technologies has less than a year of cash runway if free cash flow continues to reduce at historical rates of -13.1% each year.
X
Financial health checks
We assess Genetic Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Genetic Technologies has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

DU8 Dividends

 What is Genetic Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Genetic Technologies dividends.
If you bought €2,000 of Genetic Technologies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Genetic Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Genetic Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:DU8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 12 Stocks 0.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 321 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 1%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Genetic Technologies has not reported any payouts.
  • Unable to verify if Genetic Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Genetic Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Genetic Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Genetic Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Genetic Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Genetic Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

DU8 Management

 What is the CEO of Genetic Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
George Muchnicki
COMPENSATION A$99,037
AGE 62
TENURE AS CEO 0.5 years
CEO Bio

Dr. Jerzy Muchnicki, MBBS, also known as George, serves Chairman at Genetic Technologies Limited and Non-Executive Director at Genetic Technologies Limited since January 31, 2018. He served as Business Development Director at Genetic Technologies Limited. Dr. Muchnicki is the Interim Chief Executive Officer at Genetic Technologies Limited since September 24, 2019. He has been mostly involved and has extensive experience in commercialisation and funding R&D in the biotechnology sector from gene silencing to regenerative medicine. Dr Muchnicki has strong commercial and medical skills, including broad interests in software development, blockchain and sustainable building materials. He is a co-founder of Speed Panel Holdings a world leader in fire rated and acoustic wall solutions. He is also the co-founder of Candlebets, a software development company that is creating blockchain enabled platforms for the gaming industry. Dr. Muchnicki graduated from Monash University and has vast experience having held positions in private practice to head of student health at Melbourne University.

CEO Compensation
  • George's compensation has increased whilst company is loss making.
  • George's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Genetic Technologies management team in years:

0.7
Average Tenure
59
Average Age
  • The average tenure for the Genetic Technologies management team is less than 2 years, this suggests a new team.
Management Team

George Muchnicki

TITLE
Chairman & Interim CEO
COMPENSATION
A$99K
AGE
62
TENURE
0.5 yrs

Richard Allman

TITLE
Scientific Director
COMPENSATION
A$302K
AGE
59
TENURE
7.3 yrs

Paul Keith Viney

TITLE
Consultant
COMPENSATION
A$180K
TENURE
0.7 yrs

Phillip Hains

TITLE
Chief Financial Officer
AGE
59
TENURE
0.7 yrs

Justyn Stedwell

TITLE
Company Secretary
AGE
38
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the Genetic Technologies board of directors in years:

2.2
Average Tenure
60.5
Average Age
  • The average tenure for the Genetic Technologies board of directors is less than 3 years, this suggests a new board.
Board of Directors

George Muchnicki

TITLE
Chairman & Interim CEO
COMPENSATION
A$99K
AGE
62

Lindsay Wakefield

TITLE
Non-Executive Director
COMPENSATION
A$79K
AGE
61
TENURE
5.5 yrs

Peter Rubinstein

TITLE
Non-Executive Director
COMPENSATION
A$81K
AGE
53
TENURE
2.2 yrs

Nick Burrows

TITLE
Non-Executive Director
AGE
60
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
22. Oct 19 Sell Jimmy Thomas Individual 18. Oct 19 18. Oct 19 -14,487,786 €0.00 €-44,544
17. Sep 19 Buy Jimmy Thomas Individual 26. Jul 19 12. Sep 19 25,802,406 €0.01 €80,460
04. Jul 19 Buy Jimmy Thomas Individual 08. Apr 19 03. Jul 19 142,170,000 €0.01 €631,429
X
Management checks
We assess Genetic Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Genetic Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

DU8 News

Simply Wall St News

DU8 Company Info

Description

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women’s health in Australia and the United States. The company’s lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company also engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. In addition, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.

Details
Name: Genetic Technologies Limited
DU8
Exchange: DB
Founded: 1989
A$11,238,164
4,063,134,143
Website: http://www.gtglabs.com
Address: Genetic Technologies Limited
60-66 Hanover Street,
Fitzroy,
Victoria, 3065,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX GTG Ordinary Shares Australian Securities Exchange AU AUD 02. Jan 1992
OTCPK GNTL.F Ordinary Shares Pink Sheets LLC US USD 02. Jan 1992
DB DU8 Ordinary Shares Deutsche Boerse AG DE EUR 02. Jan 1992
CHIA GTG Ordinary Shares Chi-X Australia AU AUD 02. Jan 1992
NasdaqCM GENE NEW SPONSRD ADR Nasdaq Capital Market US USD 06. Apr 2005
Number of employees
Current staff
Staff numbers
0
Genetic Technologies employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/29 22:46
End of day share price update: 2020/03/27 00:00
Last earnings filing: 2020/02/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.